Elite Pharmaceuticals (ELTP)

Elite Pharmaceuticals (ELTP) Stock Price & Analysis


ELTP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.03 - $0.05
Previous Close$0.03
Average Volume (3M)279.89K
Market Cap
Enterprise Value$33.26M
Total Cash (Recent Filing)$17.91M
Total Debt (Recent Filing)$15.98M
Price to Earnings (P/E)4.6
Jun 14, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,013,915,081
10 Day Avg. Volume215,177
30 Day Avg. Volume279,895
Standard Deviation0.15
Financial Highlights & Ratios
Price to Book (P/B)1.51
Price to Sales (P/S)3.62
Price to Cash Flow (P/CF)-15.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit2.25
Enterprise Value/Ebitda4.31
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Elite Pharmaceuticals’s price range in the past 12 months?
Elite Pharmaceuticals lowest stock price was $0.03 and its highest was $0.05 in the past 12 months.
    What is Elite Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Elite Pharmaceuticals’s upcoming earnings report date?
    Elite Pharmaceuticals’s upcoming earnings report date is Jun 14, 2023 which is in 6 days.
      How were Elite Pharmaceuticals’s earnings last quarter?
      Elite Pharmaceuticals released its earnings results on Feb 14, 2023. The company reported $0.003 earnings per share for the quarter, beating the consensus estimate of N/A by $0.003.
        Is Elite Pharmaceuticals overvalued?
        According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Elite Pharmaceuticals pay dividends?
          Elite Pharmaceuticals does not currently pay dividends.
          What is Elite Pharmaceuticals’s EPS estimate?
          Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Elite Pharmaceuticals have?
          Elite Pharmaceuticals has 1,013,915,100 shares outstanding.
            What happened to Elite Pharmaceuticals’s price movement after its last earnings report?
            Elite Pharmaceuticals reported an EPS of $0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Elite Pharmaceuticals?
              Among the largest hedge funds holding Elite Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Elite Pharmaceuticals’s shares valued at N/A.


                Elite Pharmaceuticals Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Elite Pharmaceuticals

                Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment comprises the branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Ampio Pharmaceuticals
                Galectin Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis